Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: Experiences from a two-year randomized study

Arthritis Research and Therapy

Volumn 10, Issue 6, 2008, Pages

  Engvall, Inga Lill ^a   Svensson, Björn ^b   Tengstrand, Birgitta ^a   Brismar, Kerstin ^c   Hafström, Ingiäld ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; PREDNISOLONE; PROCOLLAGEN; SOMATOMEDIN C; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; BONE DEFECT; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; LOW DRUG DOSE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; BLOOD; BONE DEVELOPMENT; COMPARATIVE STUDY; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; RADIOGRAPHY; TIME;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOGENESIS; PREDNISOLONE; TIME FACTORS;

EID: 56849118445     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2542     Document Type: Article

References (49)

1. Deodhar AA Woolf AD Bone mass measurement and bone metabolism in rheumatoid arthritis: A review Br J Rheumatol 1996, 35:309-322. 10.1093/ rheumatology/35.4.309 8624634
2. Hooyman JR Melton LJ 3rd Nelson AM O'Fallon WM Riggs BL Fractures after rheumatoid arthritis. A population-based study Arthritis Rheum 1984, 27:1353-1361. 10.1002/art.1780271205 6508860
3. Spector TD Hall GM McCloskey EV Kanis JA Risk of vertebral fracture in women with rheumatoid arthritis BMJ 1993, 306-558. 8461772
4. Bonnick SL Shulman L Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both? Am J Med 2006, 119:S25-31. 10.1016/j.amjmed.2005.12.020 16563938
5. Dolan AL Moniz C Abraha H Pitt P Does active treatment of rheumatoid arthritis limit disease-associated bone loss? Rheumatology (Oxford) 2002, 41:1047-1051. 10.1093/rheumatology/41.9.1047 12209040
6. Vis M Wolbink GJ Lodder MC Kostense PJ Stadt van de RJ de Koning MH Dijkmans BA Lems WF Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab Arthritis Rheum 2003, 48:2996-2997. 10.1002/art.11292 14558111
7. Kirwan JR The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group N Engl J Med 1995, 333:142-146. 10.1056/ NEJM199507203330302 7791815
8. van Everdingen AA Jacobs JW Siewertsz Van Reesema DR Bijlsma JW Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial Ann Intern Med 2002, 136:1-12. 11777359
9. Svensson B Boonen A Albertsson K Heijde van der D Keller C Hafstrom I Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial Arthritis Rheum 2005, 52:3360-3370. 10.1002/art.21298 16255010
10. Sambrook PN Cohen ML Eisman JA Pocock NA Champion GD Yeates MG Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: A longitudinal study Ann Rheum Dis 1989, 48:535-538. 10.1136/ard.48.7.535 2774695
11. Laan RF van Riel PL Putte van de LB van Erning LJ van't Hof MA Lemmens JA Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study Ann Intern Med 1993, 119:963-968. 8105737
12. Verhoeven AC Boers M Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases J Rheumatol 1997, 24:1495-1503. 9263141
13. Strand V Simon LS Low dose glucocorticoids in early rheumatoid arthritis Clin Exp Rheumatol 2003, 21:S186-190. 14969074
14. Mazziotti G Angeli A Bilezikian JP Canalis E Giustina A Glucocorticoid-induced osteoporosis: An update Trends Endocrinol Metab 2006, 17:144-149. 10.1016/j.tem.2006.03.009 16678739
15. Tengstrand B Larsson E Klareskog L Hafstrom I Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: Effects on inflammation and bone mineral density Scand J Rheumatol 2007, 36:351-358. 10.1080/03009740701394021 17963164
16. Delmas PD Eastell R Garnero P Seibel MJ Stepan J The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation Osteoporos Int 2000, 11(Suppl 6):S2-17. 10.1007/s001980070002 11193237
17. Nishizawa Y Nakamura T Ohata H Kushida K Gorai I Shiraki M Fukunaga M Hosoi T Miki T Nakatsuka K Miura M Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001) J Bone Miner Metab 2001, 19:338-344. 10.1007/s007740170002 11685648
18. Garnero P Ferreras M Karsdal MA Nicamhlaoibh R Risteli J Borel O Qvist P Delmas PD Foged NT Delaisse JM The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation J Bone Miner Res 2003, 18:859-867. 10.1359/jbmr.2003.18.5.859 12733725
19. Chopin F Garnero P le Henanff A Debiais F Daragon A Roux C Sany J Wendling D Zarnitsky C Ravaud P Thomas T Long term effects of Infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis Ann Rheum Dis 2008, 67:353-357. 10.1136/ard.2007.076604 17644538
20. Delany AM Pash JM Canalis E Cellular and clinical perspectives on skeletal insulin-like growth factor I J Cell Biochem 1994, 55:328-333. 10.1002/jcb.240550309 7962164
21. Toussirot E Nguyen NU Dumoulin G Aubin F Cedoz JP Wendling D Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis Rheumatology (Oxford) 2005, 44:120-125. 10.1093/rheumatology/ keh421 15466894
22. Svensson B Schaufelberger C Teleman A Theander J Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy Rheumatology (Oxford) 2000, 39:1031-1036. 10.1093/rheumatology/39.9.1031 10986311
23. Arnett FC Edworthy SM Bloch DA McShane DJ Fries JF Cooper NS Healey LA Kaplan SR Liang MH Luthra HS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302 3358796
24. Ekdahl C Eberhardt K Andersson SI Svensson B Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire Scand J Rheumatol 1988, 17:263-271. 10.3109/03009748809098795 3187457
25. Lewiecki EM Baim S Binkley N Bilezikian JP Kendler DL Hans DB Silverman S Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions South Med J 2008, online. 18580720
26. Lunar Operator manual, Expert-XL software version 1.7. Lunar Corporation Lunar Corporation Madison, USA 1998
27. Bang P Eriksson U Sara V Wivall IL Hall K Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: Improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand Acta Endocrinol (Copenh) 1991, 124:620-629. 2068892
28. Hilding A Brismar K Degerblad M Thoren M Hall K Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects J Clin Endocrinol Metab 1995, 80:2646-2652. 10.1210/jc.80.9.2646 7545695
29. Als OS Gotfredsen A Christiansen C The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state Arthritis Rheum 1985, 28:369-375. 10.1002/art.1780280403 3986005
30. Butler RC Davie MW Worsfold M Sharp CA Bone mineral content in patients with rheumatoid arthritis: Relationship to low-dose steroid therapy Br J Rheumatol 1991, 30:86-90. 10.1093/rheumatology/30.2.86 2012961
31. Delaney MLM Metabolic Bone Disease Kelley's Textbook of Rheumatology USA: WB Saunders Company Ruddy S, Harris E, Sledge C 6 2001, 2:1635-1652.
32. van Staa TP Leufkens HG Cooper C The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis Osteoporos Int 2002, 13:777-787. 10.1007/s001980200108 12378366
33. Canalis E Mechanisms of glucocorticoid-induced osteoporosis Curr Opin Rheumatol 2003, 15:454-457. 10.1097/00002281-200307000-00013 12819474
34. Khosla S Melton LJ 3rd Riggs BL Osteoporosis: Gender differences and similarities Lupus 1999, 8:393-396. 10.1177/096120339900800513 10455520
35. Gough AK Peel NF Eastell R Holder RL Lilley J Emery P Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis Ann Rheum Dis 1994, 53:14-17. 10.1136/ard.53.1.14 8311548
36. Lems WF Gerrits MI Jacobs JW van Vugt RM van Rijn HJ Bijlsma JW Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis Ann Rheum Dis 1996, 55:288-293. 10.1136/ard.55.5.288 8660101
37. Sassi ML Aman S Hakala M Luukkainen R Risteli J Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis Clin Chem Lab Med 2003, 41:1038-1044. 10.1515/ CCLM.2003.160 12964811
38. Kotaniemi A Isomaki H Hakala M Risteli L Risteli J Increased type I collagen degradation in early rheumatoid arthritis J Rheumatol 1994, 21:1593-1596. 7799334
39. Paimela L Leirisalo-Repo M Risteli L Hakala M Helve T Risteli J Type I collagen degradation product in serum of patients with early rheumatoid arthritis: Relationship to disease activity and radiological progression in a 3-year follow-up Br J Rheumatol 1994, 33:1012-1016. 10.1093/ rheumatology/33.11.1012 7981987
40. Lems WF Van Veen GJ Gerrits MI Jacobs JW Houben HH Van Rijn HJ Bijlsma JW Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers Br J Rheumatol 1998, 37:27-33. 10.1093/rheumatology/37.1.27 9487247
41. Catrina AI Lampa J Ernestam S af Klint E Bratt J Klareskog L Ulfgren AK Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis Rheumatology (Oxford) 2002, 41:484-489. 10.1093/ rheumatology/41.5.484 12011369
42. Jassal SK von Muhlen D Barrett-Connor E Rosen CJ Serum insulin-like growth factor binding protein-1 levels and bone mineral density in older adults: The Rancho Bernardo Study Osteoporos Int 2005, 16:1948-1954. 10.1007/s00198-005-1973-6 16088361
43. Dong F Ren J Insulin-like growth factors (IGFs) and IGF-binding proteins in nephrotic syndrome children on glucocorticoid Pharmacol Res 2003, 48:319-323. 10.1016/S1043-6618(03)00182-8 12902201
44. Zhou X Loke KY Pillai CC How HK Yap HK Lee KO IGFs and IGF-binding proteins in short children with steroid-dependent nephrotic syndrome on chronic glucocorticoids: Changes with 1 year exogenous GH Eur J Endocrinol 2001, 144:237-243. 10.1530/eje.0.1440237 11248742
45. Prummel MF Wiersinga WM Oosting H Endert E The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-1 J Endocrinol Invest 1996, 19:620-623. 8957747
46. Sarzi-Puttini P Atzeni F Scholmerich J Cutolo M Straub RH Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3 Ann Rheum Dis 2006, 65:301-305. 10.1136/ ard.2005.040816 16079165
47. Bang P Degerblad M Thoren M Schwander J Blum W Hall K Insulin-like growth factor (IGF) I and II and IGF binding protein (IGFBP) 1, 2 and 3 in serum from patients with Cushing's syndrome Acta Endocrinol (Copenh) 1993, 128:397-404. 7686320
48. Canalis E Avioli L Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells J Bone Miner Res 1992, 7:1085-1092. 1414501
49. O'Connor JC McCusker RH Strle K Johnson RW Dantzer R Kelley KW Regulation of IGF-I function by proinflammatory cytokines: At the interface of immunology and endocrinology Cell Immunol 2008, 252:91-110. 10.1016/j.cellimm.2007.09.010 18325486